ARAF is altered in 2.52% of cutaneous melanoma patients [2].

ARAF is an inclusion eligibility criterion in 1 clinical trial for cutaneous melanoma, of which 1 is open and 0 are closed. Of the trial that contains ARAF status and cutaneous melanoma as inclusion criteria, 1 is phase 1 (1 open) [3].

BRAF is altered in 41.18% of cutaneous melanoma patients [2].

BRAF is an inclusion eligibility criterion in 12 clinical trials for cutaneous melanoma, of which 10 are open and 2 are closed. Of the trials that contain BRAF status and cutaneous melanoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 6 are phase 2 (4 open), and 2 are phase 3 (2 open) [3].

CRKL is altered in 3.0% of cutaneous melanoma patients [2].

CRKL is an inclusion eligibility criterion in 1 clinical trial for cutaneous melanoma, of which 1 is open and 0 are closed. Of the trial that contains CRKL status and cutaneous melanoma as inclusion criteria, 1 is phase 1 (1 open) [3].

GNA11 is altered in 1.66% of cutaneous melanoma patients [2].

GNA11 is an inclusion eligibility criterion in 1 clinical trial for cutaneous melanoma, of which 1 is open and 0 are closed. Of the trial that contains GNA11 status and cutaneous melanoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

GNAQ is altered in 1.8% of cutaneous melanoma patients [2].

GNAQ is an inclusion eligibility criterion in 1 clinical trial for cutaneous melanoma, of which 1 is open and 0 are closed. Of the trial that contains GNAQ status and cutaneous melanoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

HRAS is altered in 1.97% of cutaneous melanoma patients [2].

HRAS is an inclusion eligibility criterion in 1 clinical trial for cutaneous melanoma, of which 1 is open and 0 are closed. Of the trial that contains HRAS status and cutaneous melanoma as inclusion criteria, 1 is phase 1 (1 open) [3].

KRAS is altered in 2.61% of cutaneous melanoma patients [2].

KRAS is an inclusion eligibility criterion in 2 clinical trials for cutaneous melanoma, of which 2 are open and 0 are closed. Of the trials that contain KRAS status and cutaneous melanoma as inclusion criteria, 2 are phase 1 (2 open) [3].

MAP2K1 is altered in 7.63% of cutaneous melanoma patients [2].

MAP2K1 is an inclusion eligibility criterion in 1 clinical trial for cutaneous melanoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 status and cutaneous melanoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MAP2K2 is altered in 3.26% of cutaneous melanoma patients [2].

MAP2K2 is an inclusion eligibility criterion in 1 clinical trial for cutaneous melanoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K2 status and cutaneous melanoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MAP2K4 is altered in 1.82% of cutaneous melanoma patients [2].

MAP2K4 is an inclusion eligibility criterion in 1 clinical trial for cutaneous melanoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K4 status and cutaneous melanoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MAP3K1 is altered in 4.06% of cutaneous melanoma patients [2].

MAP3K1 is an inclusion eligibility criterion in 1 clinical trial for cutaneous melanoma, of which 1 is open and 0 are closed. Of the trial that contains MAP3K1 status and cutaneous melanoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MAPK1 is altered in 1.77% of cutaneous melanoma patients [2].

MAPK1 is an inclusion eligibility criterion in 1 clinical trial for cutaneous melanoma, of which 1 is open and 0 are closed. Of the trial that contains MAPK1 status and cutaneous melanoma as inclusion criteria, 1 is phase 1 (1 open) [3].

NF1 is altered in 24.72% of cutaneous melanoma patients [2].

NF1 is an inclusion eligibility criterion in 1 clinical trial for cutaneous melanoma, of which 1 is open and 0 are closed. Of the trial that contains NF1 status and cutaneous melanoma as inclusion criteria, 1 is phase 1 (1 open) [3].

NRAS is altered in 25.73% of cutaneous melanoma patients [2].

NRAS is an inclusion eligibility criterion in 4 clinical trials for cutaneous melanoma, of which 4 are open and 0 are closed. Of the trials that contain NRAS status and cutaneous melanoma as inclusion criteria, 3 are phase 1 (3 open) and 1 is phase 2 (1 open) [3].

PRKCA is altered in 0.75% of cutaneous melanoma patients [2].

PRKCA is an inclusion eligibility criterion in 1 clinical trial for cutaneous melanoma, of which 1 is open and 0 are closed. Of the trial that contains PRKCA status and cutaneous melanoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PRKCB is an inclusion eligibility criterion in 1 clinical trial for cutaneous melanoma, of which 1 is open and 0 are closed. Of the trial that contains PRKCB status and cutaneous melanoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PRKCD is an inclusion eligibility criterion in 1 clinical trial for cutaneous melanoma, of which 1 is open and 0 are closed. Of the trial that contains PRKCD status and cutaneous melanoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PRKCE is an inclusion eligibility criterion in 1 clinical trial for cutaneous melanoma, of which 1 is open and 0 are closed. Of the trial that contains PRKCE status and cutaneous melanoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PRKCG is an inclusion eligibility criterion in 1 clinical trial for cutaneous melanoma, of which 1 is open and 0 are closed. Of the trial that contains PRKCG status and cutaneous melanoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PRKCI is altered in 2.9% of cutaneous melanoma patients [2].

PRKCI is an inclusion eligibility criterion in 1 clinical trial for cutaneous melanoma, of which 1 is open and 0 are closed. Of the trial that contains PRKCI status and cutaneous melanoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PRKCQ is an inclusion eligibility criterion in 1 clinical trial for cutaneous melanoma, of which 1 is open and 0 are closed. Of the trial that contains PRKCQ status and cutaneous melanoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PRKCZ is altered in 0.96% of cutaneous melanoma patients [2].

PRKCZ is an inclusion eligibility criterion in 1 clinical trial for cutaneous melanoma, of which 1 is open and 0 are closed. Of the trial that contains PRKCZ status and cutaneous melanoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

RAF1 is altered in 4.66% of cutaneous melanoma patients [2].

RAF1 is an inclusion eligibility criterion in 1 clinical trial for cutaneous melanoma, of which 1 is open and 0 are closed. Of the trial that contains RAF1 status and cutaneous melanoma as inclusion criteria, 1 is phase 1 (1 open) [3].

SRC is altered in 1.95% of cutaneous melanoma patients [2].

SRC is an inclusion eligibility criterion in 1 clinical trial for cutaneous melanoma, of which 1 is open and 0 are closed. Of the trial that contains SRC status and cutaneous melanoma as inclusion criteria, 1 is phase 1 (1 open) [3].